CVR number 40447148
Industry 72.1100 Research and experimental development on biotechnology

Accelerbiotics ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2016
N/A
2017
N/A
2018
N/A
2019
2020/4
2020
2021/4
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.0% 0.0% 0.0% 9.5% 17.6%  
Credit score (0-100)  0 0 0 27 9  
Credit rating  N/A N/A N/A B B  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2016
N/A
2017
N/A
2018
N/A
2019
2020/4
2020
2021/4
Net sales  0 0 0 0 0  
Gross profit  0.0 0.0 0.0 -2.8 68.9  
EBITDA  0.0 0.0 0.0 -2.8 68.9  
EBIT  0.0 0.0 0.0 -2.8 68.9  
Pre-tax profit (PTP)  0.0 0.0 0.0 -2.8 68.8  
Net earnings  0.0 0.0 0.0 -2.1 53.7  
Pre-tax profit without non-rec. items  0.0 0.0 0.0 -2.8 68.8  
 
See the entire income statement

Balance sheet (kDKK) 
2016
N/A
2017
N/A
2018
N/A
2019
2020/4
2020
2021/4
Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  0.0 0.0 0.0 47.9 102  
Interest-bearing liabilities  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0.0 0.0 0.0 47.9 116  
Net Debt  0.0 0.0 0.0 -47.1 -104  
 
See the entire balance sheet

Volume 
2016
N/A
2017
N/A
2018
N/A
2019
2020/4
2020
2021/4
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 0.0 0.0 -2.8 68.9  
Gross profit growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 0 0 48 116  
Balance sheet change%  0.0% 0.0% 0.0% 0.0% 142.6%  
Added value  0.0 0.0 0.0 -2.8 68.9  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 0.0 0.0 -1.0 1.0  

Profitability 
2016
N/A
2017
N/A
2018
N/A
2019
2020/4
2020
2021/4
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% 0.0% 0.0% 100.0% 100.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% 0.0% 0.0% -5.7% 84.1%  
ROI %  0.0% 0.0% 0.0% -5.7% 92.3%  
ROE %  0.0% 0.0% 0.0% -4.5% 71.9%  

Solidity 
2016
N/A
2017
N/A
2018
N/A
2019
2020/4
2020
2021/4
Equity ratio %  0.0% 0.0% 0.0% 100.0% 87.5%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% 0.0% 0.0% 1,711.4% -150.6%  
Gearing %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 0.0% 0.0%  

Liquidity 
2016
N/A
2017
N/A
2018
N/A
2019
2020/4
2020
2021/4
Quick Ratio  0.0 0.0 0.0 0.0 8.0  
Current Ratio  0.0 0.0 0.0 0.0 8.0  
Cash and cash equivalent  0.0 0.0 0.0 47.1 103.8  

Capital use efficiency 
2016
N/A
2017
N/A
2018
N/A
2019
2020/4
2020
2021/4
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 0.0 0.0 47.3 101.6  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2016
N/A
2017
N/A
2018
N/A
2019
2020/4
2020
2021/4
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0